| Water Tower Research Highlights Ainos' Significant Commercial Traction and Strategic Milestones Across Multiple Sectors |
412% revenue growth reflects AI Nose sales in elderly care Expanding AI-driven scent tech beyond healthcare into robotics and industrial applications SAN DIEGO, CALIFORNIA / ACCESS Newswire / May 14, 2025 / Ainos, Inc. (Nasdaq:AIMD)(Nasdaq:AIMDW) ("Ainos"), a leader in AI-powered scent digitization, today announced that Water Tower Research ("WTR") has published a report highlighting the Company's significant progress in commercializing its AI-driven scent digitization platform, AI Nose, and expanding into multiple market verticals. Notably, Ainos has achieved a key milestone of achieving over 80% accuracy in its senior care project. |
accessnewswire.com |
2025-05-14 12:00:00 |
Czytaj oryginał (ang.) |
| Ainos Reports First Quarter 2025 Financial Results |
Q1 revenues increased 412% year over year, driven by AI Nose products Delivers strong turnaround from gross loss to gross profit in Q1 AI Nose gains traction beyond healthcare with strategic partnerships in robotics and semiconductor sectors VELDONA® program advances with TFDA and IRB Approvals for two clinical trials in Taiwan SAN DIEGO, CALIFORNIA / ACCESS Newswire / May 12, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos", or the "Company") today announced its financial results for the first quarter ended March 31, 2025. Chun-Hsien (Eddy) Tsai, Chairman of the Board, President, and Chief Executive Officer of Ainos, commented, "Q1 2025 represents a significant step forward in advancing our long-term strategy to build a differentiated healthcare and technology company powered by scent digitization, AI-enhanced diagnostics and innovative therapeutics. |
accessnewswire.com |
2025-05-12 12:00:00 |
Czytaj oryginał (ang.) |
| Water Tower Research Spotlights Ainos' Smell Integration in Humanoid Robot - AI Smelltech is Progressing Rapidly |
Robotic smelltech by AI Nose moves from concept to integration in weeks Partnership fast-tracks robotic smell integration as global service robotics market nears $40.6B, Japan $1.2B SAN DIEGO, CALIFORNIA / ACCESS Newswire / April 23, 2025 / Ainos, Inc. (Nasdaq:AIMD)(Nasdaq:AIMDW) ("Ainos"), a leader in AI-powered scent digitization, today announced that Water Tower Research ("WTR") has published a report highlighting the Company's successful installation of its AI Nose technology onto a humanoid robot developed by ugo, Inc., Japan's leading service robot company. The milestone, achieved just weeks after announcing the partnership, demonstrates fast execution and marks a global first in robotic smell integration. |
accessnewswire.com |
2025-04-23 12:00:00 |
Czytaj oryginał (ang.) |
| Ainos and ugo Complete First Robotic Smell Integration in Japan |
Milestone Ignites a New Era of Smell-Enabled Robotics Installs AI Nose in ugo Robot; Real-World Pilots to Begin in Weeks SAN DIEGO, CA / ACCESS Newswire / April 21, 2025 / Ainos, Inc. (Nasdaq:AIMD)(Nasdaq:AIMDW) ("Ainos"), a leader in AI-powered scent digitization, has successfully installed its proprietary AI Nose olfaction module on a humanoid robot developed by ugo, Inc. ("ugo"), Japan's top service robotics company. Completed on April 9, 2025, the installation marks the world's first robot with a functional sense of smell, a breakthrough that redefines the frontier of robotics, AI, and human-machine interaction. |
accessnewswire.com |
2025-04-21 12:00:00 |
Czytaj oryginał (ang.) |
| Ainos Secures TFDA Approval and IRB Clearance to Advance VELDONA Clinical Trials for HIV Oral Warts and Sjögren's Syndrome in Taiwan |
Dual Trials Accelerate VELDONA® Toward Rare Disease Market Entry Bridging Strategy Aims to Fast-Track U.S. Regulatory Approvals SAN DIEGO, CALIFORNIA / ACCESS Newswire / April 14, 2025 / Ainos, Inc. (Nasdaq:AIMD, AIMDW) ("Ainos" or the "Company"), pioneer of low-dose oral interferon therapeutics, today announced significant progress in advancing its oral interferon drug platform, VELDONA® in the rare disease space. The Taiwan Food and Drug Administration (TFDA) has approved the Company's clinical trial for human immunodeficiency virus (HIV)-related oral warts, while Institutional Review Board (IRB) clearance has been granted for its upcoming Sjögren's Syndrome (pSS) study. |
accessnewswire.com |
2025-04-14 12:00:00 |
Czytaj oryginał (ang.) |
| Water Tower Research Highlights Ainos' AI Nose Expansion into Robotics and Semiconductor Manufacturing - Smell ID Is Scaling |
Strategic partnerships and industry-leading accuracy position Ainos as a game-changer in digitized scent technology SAN DIEGO, CALIFORNIA / ACCESS Newswire / April 11, 2025 / Ainos, Inc. (NASDAQ:AIMD, AIMDW) ("Ainos" or the "Company"), a leader in AI-powered scent digitization, today announced that Water Tower Research ("WTR") has published a report spotlighting the Company's expansion of its AI Nose technology into the robotics and semiconductor sectors. The report features insights from a management fireside chat on April 8, 2025. |
accessnewswire.com |
2025-04-11 12:00:00 |
Czytaj oryginał (ang.) |
| Ainos to Participate in Fireside Chat with Water Tower Research on April 8, 2025 |
SAN DIEGO, CALIFORNIA / ACCESS Newswire / March 24, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a leader in AI-powered scent digitization, today announced that it will participate in a fireside chat with Do Kim, senior research analyst of Water Tower Research ("WTR") and John Roy, managing director of WTR on Tuesday, April 8, 2025, at 10:00 a.m. ET. Ainos will provide insights into AI Nose applications, including its use in smart manufacturing and robots, as well as the impact of AI-driven digitized smell on industries beyond healthcare. |
accessnewswire.com |
2025-03-24 19:00:00 |
Czytaj oryginał (ang.) |
| Water Tower Research Spotlights Ainos & ASE Partnership: Unleashing AI Nose's Potential in Chip Manufacturing and More |
Another key win in expanding AI Nose's industrial opportunities Partnership to integrate AI Nose into ASE's factories and explore broader industrial use-cases SAN DIEGO, CALIFORNIA / ACCESS Newswire / March 13, 2025 / Ainos, Inc. (NASDAQ:AIMD, AIMDW) ("Ainos" or the "Company"), a leader in AI-powered scent digitization, today announced that Water Tower Research ("WTR") has published a report spotlighting Ainos' strategic collaboration with Advanced Semiconductor Engineering, Inc. ("ASE"), the world's largest provider of semiconductor packaging and testing services. The partnership will integrate Ainos' AI Nose, an AI-powered electric nose technology, into ASE's factories, expanding AI Nose's opportunity in semiconductor manufacturing. |
accessnewswire.com |
2025-03-13 11:00:00 |
Czytaj oryginał (ang.) |
| Ainos and ASE Partner to Power AI Scent Digitization in Semiconductor Manufacturing |
Harnessing AI-Powered Scent Digitization for Smarter, Safer, and More Sustainable Factories SAN DIEGO, CA / ACCESS Newswire / March 11, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a leader in AI-driven scent digitization, has announced a strategic collaboration with Advanced Semiconductor Engineering, Inc. (ASE), the world's largest provider of semiconductor packaging and testing services. This partnership aims to revolutionize semiconductor manufacturing by leveraging Ainos' patented AI Nose technology to analyze airborne chemicals into "Smell IDs", enhancing process efficiency, environmental safety, and environmental, social, and governance (ESG) compliance. |
accessnewswire.com |
2025-03-11 11:00:00 |
Czytaj oryginał (ang.) |
| Ainos Reports Full Year 2024 Financial Results |
Unveiled revolutionary AI Nose for robotics application, inviting global robotics companies to join Ainos Alliance in shaping the future of smell-enabled robots Advanced VELDONA® development with key Japan patent, Taiwan Tanabe partnership, and IRB approval for Sjögren's syndrome clinical study SAN DIEGO, CALIFORNIA / ACCESS Newswire / March 7, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQAIMDW) ("Ainos", or the "Company") today announced its financial results for the fiscal year ended December 31, 2024. Chun-Hsien (Eddy) Tsai, Chairman of the Board, President, and Chief Executive Officer of Ainos, commented, "2024 marked another pivotal year as we transitioned from our COVID-19 antigen rapid test business to advancing the VELDONA® and pioneering AI Nose programs. |
accessnewswire.com |
2025-03-07 18:45:00 |
Czytaj oryginał (ang.) |
| Water Tower Research Highlights Ainos & ugo Partnership: The Final Sense for Robots - AI Smell is Here |
Practical partnership for AI Nose, multiple new opportunities AI Nose to change robotics landscape with first AI smell sensing SAN DIEGO, CA / ACCESS Newswire / March 7, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a pioneer of smell digitization, today announced that Water Tower Research ("WTR") has published a report on the Company's strategic partnership with ugo, Inc., a leading Japanese service robotics company. The collaboration will integrate Ainos' innovative AI Nose technology into ugo's service robots, marking a milestone in digitizing olfactory sensing. |
accessnewswire.com |
2025-03-07 15:30:00 |
Czytaj oryginał (ang.) |
| Ainos and ugo to Develop the World's First Robot With a Sense of Smell |
A Major Breakthrough in Ainos' Mission to Digitize Scent First-ever Smell-Enabled Robotics Will Unlock New Revenue Streams in Smart Manufacturing, Public Safety and more SAN DIEGO, CA / ACCESS Newswire / March 5, 2025 / Ainos, Inc. (Nasdaq:AIMD)(Nasdaq:AIMDW), a pioneer of smell digitization, and ugo, Inc., Japan's largest service robot company by market share1, today announced a strategic partnership to integrate Ainos' AI Nose technology with ugo's autonomous robotic platform. This collaboration will mark a major milestone in the digitization of smell, unlocking new capabilities for robots in industrial safety, healthcare, and public security. |
accessnewswire.com |
2025-03-05 12:00:00 |
Czytaj oryginał (ang.) |
| Ainos Achieves Major Breakthrough: Japan Patent Approval for VELDONA Redefines Antiviral Innovation |
Revolutionary Oral Interferon Technology Combines Unmatched Advantages and Global Potential in the $16 Billion Coronavirus Market SAN DIEGO, CA / ACCESS Newswire / January 27, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company") proudly announces the granting of a pivotal invention patent in Japan (Patent No. 7619659) for its groundbreaking oral interferon formulation, VELDONA®, to treat and prevent coronavirus infections. |
accessnewswire.com |
2025-01-27 12:00:00 |
Czytaj oryginał (ang.) |
| Water Tower Research Spotlights Ainos' AI Nose Programs and Strategic Milestones for 2025 |
Report highlights greater visibility in AI Nose developments, including robotics, smart manufacturing, elderly care monitoring, and women's health testing SAN DIEGO, CA / ACCESS Newswire / January 21, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a pioneer of digiting scent and low-dose interferon therapeutics, today announced that Water Tower Research ("WTR") has published a report projecting increased visibility for the Company's transformative AI Nose programs. The report emphasizes anticipated progress for AI Nose across multiple sectors, including robotics, smart manufacturing, elderly care, and women's health. |
accessnewswire.com |
2025-01-21 12:00:00 |
Czytaj oryginał (ang.) |
| Ainos Granted 180-Day Extension by Nasdaq to Regain Compliance With Minimum Bid Price Rule |
SAN DIEGO, CA / ACCESS Newswire / January 17, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos", or the "Company"), today announced that it had received written notification (the "Written Notification") from the Listing Qualifications Department of the Nasdaq Stock Market LLC ("Nasdaq") that the Company is eligible for a 180-day extension to regain compliance with the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the "Rule"). As previously reported, on July 15, 2024, the Company received a deficiency letter from the Nasdaq notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company's common stock has been below the minimum $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to the Rule and the Company had been given 180 calendar days, or until January 13, 2025, to regain compliance with the Rule. |
accessnewswire.com |
2025-01-17 11:00:00 |
Czytaj oryginał (ang.) |
| Ainos Unveils AI Nose for Robotics: Invites Global Robotics Companies to Join Forces in Shaping the Future of Smell-Enabled Robots |
Ainos invites robotics and humanoid companies to join Ainos Alliance and digitize smell SAN DIEGO, CA / ACCESSWIRE / January 13, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW), a pioneer of digitizing scent, proudly announces its revolutionary AI Nose for robotics application and invites robotics companies worldwide to join Ainos Alliance. This technology aims to equip robots with the ability to "smell," filling a long-standing gap in sensory capabilities. |
accesswire.com |
2025-01-13 12:00:00 |
Czytaj oryginał (ang.) |
| CORRECTION BY SOURCE: Smell the Future: Ainos Elevates Health and Technology With AI Nose and VELDONA |
The following CORRECTS and REPLACES the release that was issued earlier today: Updated partner for VOC detection platform development From giving AI the sense of smell and breakthrough in rare disease treatments, Ainos is shaping 2025 with bold technologies and strategic collaborations SAN DIEGO, CA / ACCESSWIRE / December 18, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos", or the "Company"), a diversified healthcare company focused on novel AI-powered point-of-care testing ("POCT") and VELDONA ® low-dose interferon therapeutics, is pleased to provide a letter to shareholders from its Chairman of the Board, President, and Chief Executive Officer, Mr. Chun-Hsien (Eddy) Tsai. |
accesswire.com |
2024-12-18 14:05:00 |
Czytaj oryginał (ang.) |
| Smell the Future: Ainos Elevates Health and Technology With AI Nose and VELDONA |
From giving AI the sense of smell and breakthrough in rare disease treatments, Ainos is shaping 2025 with bold technologies and strategic collaborations SAN DIEGO, CA / ACCESSWIRE / December 18, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos", or the "Company"), a diversified healthcare company focused on novel AI-powered point-of-care testing ("POCT") and VELDONA ® low-dose interferon therapeutics, is pleased to provide a letter to shareholders from its Chairman of the Board, President, and Chief Executive Officer, Mr. Chun-Hsien (Eddy) Tsai. |
accesswire.com |
2024-12-18 10:00:00 |
Czytaj oryginał (ang.) |
| Ainos Joins Webull Corporate Connect Service Platform to Enhance Investor Engagement |
SAN DIEGO, CA / ACCESSWIRE / December 13, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), an innovative healthcare company focused on advanced AI-driven point-of-care testing ("POCT") and low-dose interferon therapeutics, today announced its participation in the Webull Corporate Connect Service (CCS). This initiative aims to further expand the Company's investor outreach and enhance transparency with its growing shareholder base. |
accesswire.com |
2024-12-13 10:00:00 |
Czytaj oryginał (ang.) |
| Water Tower Research Underscores Ainos' Partnership With Taiwan Tanabe Seiyaku for VELDONA Manufacturing and Marketing |
SAN DIEGO, CA / ACCESSWIRE / December 4, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), an innovative healthcare company focused on advanced AI-driven point-of-care testing ("POCT") and low-dose interferon therapeutics, today announced that Water Tower Research has issued a report highlighting Ainos' strategic partnership with Taiwan Tanabe Seiyaku for manufacturing and marketing VELDONA®, a novel therapeutic candidate for primary Sjögren's syndrome, in Taiwan. The report underscores the significance of Ainos' efforts to out-license VELDONA®, starting with this key regional partnership, and sets the stage for future global expansion. |
accesswire.com |
2024-12-04 10:00:00 |
Czytaj oryginał (ang.) |
| Ainos, Inc. Announces Strategic Partnership with Taiwan Tanabe Seiyaku to Advance Manufacturing and Taiwan Market Promotion of Sjögren's Syndrome Drug |
San Diego, California--(Newsfile Corp. - December 2, 2024) - Ainos, Inc. (NASDAQ: AIMD) (NASDAQ: AIMDW) ("Ainos" or the "Company"), an innovative healthcare company focused on advanced AI-driven point-of-care testing ("POCT") and low-dose interferon therapeutics, today proudly announced the signing of a strategically significant Memorandum of Understanding (MOU) with Taiwan Tanabe Seiyaku Co., Ltd., a subsidiary of Mitsubishi Tanabe Pharma Corporation in Japan, brings extensive pharmaceutical development and manufacturing expertise to the partnership. |
newsfilecorp.com |
2024-12-02 10:00:00 |
Czytaj oryginał (ang.) |
| Water Tower Research Highlights IRB Approval for the Ainos VELDONA Clinical Sjogren's Trial Alongside 3Q24 Earnings and Developments |
Taiwan regulatory approval for the trial expected in Q1 2025 Remains committed to a capital-efficient business strategy SAN DIEGO, CA / ACCESSWIRE / November 13, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), an innovative healthcare company focused on advanced AI-driven point-of-care testing ("POCT") and low-dose interferon therapeutics, today announced that Water Tower Research ("WTR") has published a report on the Company's obtainment of Institutional Review Board ("IRB") approval from the Shuang Ho Hospital (Taipei Medical University) to conduct the VELDONA® clinical study for primary Sjogren's syndrome, along with 3Q24 results and multiple other developments. The report said an approval from Taiwan's Food and Drug Administration (TFDA) for the study is expected in next quarter, with the trial set to start around April 2025 and completion in December 2026. |
accesswire.com |
2024-11-13 10:00:00 |
Czytaj oryginał (ang.) |
| Ainos Announces IRB Approval for Sjögren's Syndrome Clinical Study at Shuang Ho Hospital, Affiliated with Taipei Medical University, and Plans to Initiate New Phase of Treatment Evaluation in Q1 2025 |
IRB approval on track as scheduled Next step is obtaining all regulatory approvals, followed by site initiation visit VELDONA significantly increases unstimulated whole salivary flow in prior Phase 3 studies SAN DIEGO, CA / ACCESSWIRE / November 11, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos", or the "Company"), an innovative healthcare company focused on advanced AI-driven point-of-care testing ("POCT") and low-dose interferon therapeutics, today announced that it has received Institutional Review Board ("IRB") approval from Shuang Ho Hospital, affiliated with Taipei Medical University (IRB Approval No.: TMU-JIRB No. |
accesswire.com |
2024-11-11 10:00:00 |
Czytaj oryginał (ang.) |
| Ainos Takes Decisive Action to Protect Stockholder Interests and Combat Potential Illegal Trading Activities |
SAN DIEGO, CA / ACCESSWIRE / November 8, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), an innovative healthcare company focused on advanced AI-powered point-of-care testing (POCT) and low-dose interferon therapeutics, today announced it has filed complaints with NASDAQ MarketWatch and the U.S. Securities and Exchange Commission (SEC), due to concerns about unusual trading activity in its common stock, specifically large-volume sell orders. Ainos suspects that these trading activities may involve regulatory violations and urges the regulators to investigate thoroughly to uphold market fairness and protect stockholder interests. |
accesswire.com |
2024-11-08 10:00:00 |
Czytaj oryginał (ang.) |
| Ainos Reports Third Quarter 2024 Financial Results |
Secured multi-regional patent assets, strengthening Ainos' AI Nose technology. Expanded VELDONA® patent portfolio with a new invention patent for treatments and preventions for coronavirus infections. |
accesswire.com |
2024-11-06 18:30:00 |
Czytaj oryginał (ang.) |
| Ainos Expands Patent Portfolio With Strategic Shareholder's Cutting-Edge Technology Assets |
Strengthens AI Nose Gas Sensing Technology with Additional Exclusively Licensed Patents Secures Exclusive Rights to Breakthrough Nitrogen-Oxygen Separation Technology with Superior Energy Efficiency and Ultra-Low Carbon Emissions, Advancing Sustainable Medical Practices SAN DIEGO, CA / ACCESSWIRE / October 28, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), an innovative healthcare company focused on advanced AI-driven point-of-care testing ("POCT") and low-dose interferon therapeutics, today announced that it has secured exclusive licensing rights for an additional 28 multi-regional patent assets from its strategic shareholder and product co-developer, Taiwan Carbon Nano Technology Corporation ("TCNT"). These patents encompass innovations in AI Nose gas sensing technology and extend Ainos' technological capabilities with a groundbreaking nitrogen-oxygen separation technology targeting medical applications. |
accesswire.com |
2024-10-28 10:00:00 |
Czytaj oryginał (ang.) |
| Ainos Highlights VELDONA Clinical Advancements and Market Potential in Water Tower Research Spotlight Podcast |
Prioritizing VELDONA®'s development for oral warts in HIV+ patients and Sjogren's syndrome Burgeoning pet care market also presents growth opportunities for VELDONA® SAN DIEGO, CA / ACCESSWIRE / October 24, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), an innovative healthcare company focused on advanced AI-driven point-of-care testing ("POCT") and low-dose interferon therapeutics, shared promising clinical progress of VELDONA® and its growth opportunities alongside upcoming milestones in the Water Tower Research ("WTR") Small-Cap Spotlight podcast, signaling strong potential for both human and animal health markets. WTR has published a report recapping highlights from the podcast. |
accesswire.com |
2024-10-24 14:50:00 |
Czytaj oryginał (ang.) |
| Ainos Advances Healthcare and Industrial Innovations with AI Nose and VELDONA Technologies |
Ainos pioneers AI-powered digital nose technology with VOC detection breakthroughs for early disease diagnosis, industrial safety, and human-like sensory capabilities in robots VELDONA® low-dose oral interferon technology demonstrates huge potential in in viral, autoimmune, and veterinary treatments SAN DIEGO, CA / ACCESSWIRE / October 7, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), an innovative healthcare company focused on advanced AI-driven point-of-care testing ("POCT") and low-dose interferon therapeutics, today announced that it continues to push the boundaries of global smart healthcare and immunotherapy innovation. With its AI Nose and VELDONA® low-dose oral interferon technologies, Ainos is not only spearheading advancements in medical technology but also demonstrating significant potential for industrial safety and automation applications. |
accesswire.com |
2024-10-07 12:00:00 |
Czytaj oryginał (ang.) |
| Ainos, Inc. Receives IRB Approval From National Taiwan University Hospital for HIV-Oral Warts Clinical Trial, Highlighting Value of FDA-Designated Orphan Drug VELDONA |
Next step will be receiving approval from Taiwan Food and Drug Administration (TFDA) SAN DIEGO, CA / ACCESSWIRE / September 25, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), an innovative healthcare company focused on advanced AI-driven point-of-care testing ("POCT") and low-dose interferon therapeutics, today announced it has received Institutional Review Board (IRB) approval from the National Taiwan University Hospital for its clinical trial focused on treating oral warts in HIV-positive patients. This trial will evaluate VELDONA®, Ainos' low-dose oral interferon formulation, which has received orphan drug designation from the U.S. Food and Drug Administration ("FDA"), as a potential treatment for HIV-related oral warts. |
accesswire.com |
2024-09-25 12:00:00 |
Czytaj oryginał (ang.) |
| Ainos Spotlighted in Water Tower Research Report on VELDONA Clinical Study for Sjogren's Syndrome |
Sjogren's Syndrome is a rare autoimmune disease with limited treatment options Prior U.S. Phase 3 data demonstrated benefits SAN DIEGO, CA / ACCESSWIRE / September 24, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), an innovative healthcare company focused on advanced AI-driven point-of-care testing ("POCT") and low-dose interferon therapeutics, today announced that Water Tower Research ("WTR") has published a report highlighting the Company's upcoming clinical study for VELDONA® in treating primary Sjogren's syndrome, targeted to begin in December 2024 in Taiwan. The report emphasizes Ainos' capital-efficient strategy in conducting clinical trials within Taiwan. |
accesswire.com |
2024-09-24 14:55:00 |
Czytaj oryginał (ang.) |
| Ainos Announced Plan to Initiate Taiwan Clinical Study of VELDONA for Treating Sjögren's Syndrome, a Rare Disease With Limited Treatment Options |
Prior Phase 3 studies showed positive benefits in increasing unstimulated whole saliva secretion Ainos aims to complete all regulatory approvals for the study in Q4 2024 SAN DIEGO, CA / ACCESSWIRE / September 23, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), an innovative healthcare company focused on advanced AI-driven point-of-care testing (POCT) and low-dose interferon therapeutics, is pleased to announce that it plans to conduct a Taiwan clinical study for very low-dose interferon alpha (VELDONA) on treating Sjögren's syndrome at Taipei Medical University-Shuang Ho Hospital. A total of eight clinical trials have been conducted in the U.S. by the Company to evaluate the use of VELDONA® for treating Sjögren's syndrome. |
accesswire.com |
2024-09-23 12:00:00 |
Czytaj oryginał (ang.) |
| Water Tower Research Highlights Ainos VELDONA Clinical Trial for HIV+ Patients with Oral Warts |
SAN DIEGO, CA / ACCESSWIRE / September 20, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), an innovative healthcare company focused on advanced AI-driven point-of-care testing ("POCT") and low-dose interferon therapeutics, today announced that Water Tower Research ("WTR") has issued a note on the Company's upcoming clinical trial for VELDONA ® , a low-dose oral interferon-alpha formulation, in treating oral warts in HIV+ patients on antiretroviral therapy ("ART"). The report highlights Ainos' commitment to advancing cost-efficient clinical research alongside a single-site, double-blind study set to commence at the National Taiwan University Hospital ("NTUH") by November 2024. |
accesswire.com |
2024-09-20 12:00:00 |
Czytaj oryginał (ang.) |
| Ainos Announced Plan to Initiate Taiwan Clinical Study for VELDONA as Potential Treatment of Oral Warts in HIV-Seropositive Patients, an Orphan Drug Designated by the FDA |
Ainos Plans To Conduct the Study at National Taiwan University Hospital, a Premier Taiwanese Medical Center for HIV Management The U.S. FDA Have Granted Orphan Drug Designation (ODD) for the Company's VELDONA® Low-Dose Oral Interferon Formulation as a Potential Treatment for Oral Warts in HIV-Positive Patients SAN DIEGO, CA / ACCESSWIRE / September 17, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), an innovative healthcare company focused on advanced AI-driven point-of-care testing (POCT) and low-dose interferon therapeutics, is pleased to announce that its plans to initiate a clinical study for very low-dose interferon alpha (VELDONA) on treating Human immunodeficiency virus (HIV)-related oral warts at the National Taiwan University Hospital. The study aims to evaluate the efficacy of VELDONA®, a low-dose oral interferon-alpha formulation, in treating oral warts in HIV-positive patients undergoing combination antiretroviral therapy. |
accesswire.com |
2024-09-17 12:00:00 |
Czytaj oryginał (ang.) |
| Ainos Secures Taiwan Invention Patent and Advances Global Patent Protection for VELDONA, a Breakthrough in Coronavirus Treatment and Prevention |
This patent marks a major leap in Ainos' antiviral research, contributing to global efforts against coronavirus infections SAN DIEGO, CA / ACCESSWIRE / September 3, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), an innovative healthcare company focused on advanced AI-driven point-of-care testing (POCT) and low-dose interferon therapeutics, is pleased to announce that its groundbreaking VELDONA® formulation has been granted an invention patent in Taiwan and has filed for global patent protection under the Patent Cooperation Treaty (PCT). This patent represents a significant milestone in the treatment and prevention of coronavirus infections. |
accesswire.com |
2024-09-03 12:30:00 |
Czytaj oryginał (ang.) |
| Ainos to Participate in H.C. Wainwright 26th Annual Global Investment Conference |
Company invites shareholders and all interested parties to learn our journey for ultimately becoming AI's nose capable of digitizing smell. SAN DIEGO, CA / ACCESSWIRE / August 27, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos", or the "Company"), a diversified healthcare company focused on novel AI-powered point-of-care testing ("POCT") and VELDONA low-dose interferon therapeutics, today announced that it will be attending the H.C. |
accesswire.com |
2024-08-27 12:30:00 |
Czytaj oryginał (ang.) |
| Ainos CEO Highlights AI Nose Achievements and Upcoming 2H 2024 Milestones in Shareholder Letter |
Embarking on a journey to ultimately becoming AI's nose capable of digitizing smell AI Nose journey begins in healthcare and is now expanding into smart factories SAN DIEGO, CA / ACCESSWIRE / August 26, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos", or the "Company"), a diversified healthcare company focused on novel AI-powered point-of-care testing ("POCT") and VELDONA low-dose interferon therapeutics, is pleased to provide an update letter to shareholders from its Chairman of the Board, President, and Chief Executive Officer, Mr. Chun-Hsien (Eddy) Tsai. |
accesswire.com |
2024-08-26 12:30:00 |
Czytaj oryginał (ang.) |